CO2023001411A2 - Inhibidores del factor c3 del complemento y sus usos médicos - Google Patents

Inhibidores del factor c3 del complemento y sus usos médicos

Info

Publication number
CO2023001411A2
CO2023001411A2 CONC2023/0001411A CO2023001411A CO2023001411A2 CO 2023001411 A2 CO2023001411 A2 CO 2023001411A2 CO 2023001411 A CO2023001411 A CO 2023001411A CO 2023001411 A2 CO2023001411 A2 CO 2023001411A2
Authority
CO
Colombia
Prior art keywords
compstatin
introduction
modifications
inhibitors
analogues
Prior art date
Application number
CONC2023/0001411A
Other languages
English (en)
Spanish (es)
Inventor
Anne Pernille Tofteng Shelton
Henrik Fischer Munch
Rasmus Leth
Original Assignee
Zp Spv 3 K/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zp Spv 3 K/S filed Critical Zp Spv 3 K/S
Publication of CO2023001411A2 publication Critical patent/CO2023001411A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
CONC2023/0001411A 2020-07-16 2023-02-09 Inhibidores del factor c3 del complemento y sus usos médicos CO2023001411A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20186297 2020-07-16
PCT/EP2021/069798 WO2022013374A1 (en) 2020-07-16 2021-07-15 Inhibitors of complement factor c3 and their medical uses

Publications (1)

Publication Number Publication Date
CO2023001411A2 true CO2023001411A2 (es) 2023-02-16

Family

ID=71661768

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0001411A CO2023001411A2 (es) 2020-07-16 2023-02-09 Inhibidores del factor c3 del complemento y sus usos médicos

Country Status (11)

Country Link
US (1) US20230287051A1 (https=)
EP (1) EP4182023A1 (https=)
JP (1) JP2023538807A (https=)
KR (1) KR20230039718A (https=)
CN (1) CN116209671A (https=)
AU (1) AU2021309548A1 (https=)
CA (1) CA3185730A1 (https=)
CO (1) CO2023001411A2 (https=)
IL (1) IL299870A (https=)
MX (1) MX2023000679A (https=)
WO (1) WO2022013374A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020128624A (ru) 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
CN120359233A (zh) * 2022-11-24 2025-07-22 阿麦达斯制药美国有限责任公司 用于基于载体的疗法的坎普他汀类似物
CN118812653A (zh) * 2023-04-18 2024-10-22 成都奥达生物科技有限公司 一种长效坎普他汀化合物
CN119219741A (zh) * 2023-06-29 2024-12-31 刘晓蓉 新型补体抑制剂及其制备、应用和产品

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
WO1999013899A1 (en) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
PT1549333E (pt) 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
EP2662089A3 (en) 2005-10-08 2014-02-19 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
CN102977191B (zh) 2005-11-28 2016-08-10 宾夕法尼亚州大学理事会 有效的c3补体抑制素类似物
WO2008153963A1 (en) 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
CA2813049A1 (en) * 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
RU2606120C2 (ru) * 2011-08-31 2017-01-10 Хантсман Эдванст Матириалз (Свитзеленд) Гмбх Способ пропитки реакторов с воздушным сердечником, подвергнутый пропитке реактор с воздушным сердечником и применение системы пропитки
CA2847862C (en) 2011-09-07 2021-01-12 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
US9512180B2 (en) 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
US10213476B2 (en) * 2014-03-17 2019-02-26 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
RU2020128624A (ru) * 2018-02-27 2022-03-28 Зп Спв 3 К/С Аналоги компстатина и их медицинское применение
BR112022003760A2 (pt) * 2019-08-27 2022-05-31 Zp Spv 3 K/S Análogos de compstatina e seus usos médicos

Also Published As

Publication number Publication date
EP4182023A1 (en) 2023-05-24
MX2023000679A (es) 2023-04-18
CA3185730A1 (en) 2022-01-20
AU2021309548A1 (en) 2023-02-23
KR20230039718A (ko) 2023-03-21
IL299870A (en) 2023-03-01
WO2022013374A1 (en) 2022-01-20
US20230287051A1 (en) 2023-09-14
JP2023538807A (ja) 2023-09-12
CN116209671A (zh) 2023-06-02

Similar Documents

Publication Publication Date Title
CO2023001411A2 (es) Inhibidores del factor c3 del complemento y sus usos médicos
CO2020011027A2 (es) Análogos de compstatina y sus usos médicos
CO2022003556A2 (es) Análogos de compstatina y sus usos médicos
CO2021012380A2 (es) Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento
EA200901459A1 (ru) Реконструированные поверхностно-активные вещества, имеющие улучшенные свойства
MX2023006471A (es) Composiciones farmaceuticas mejoradas que contienen vector viral adenoasociado.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
ES2572260T3 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o membranas mucosas y su uso en composiciones cosméticas o farmacéuticas
ES2651946T3 (es) Utilización de péptidos CD31 en el tratamiento de trastornos trombóticos y autoinmunes
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
EA201190292A1 (ru) Улучшенная композиция реконструированных сурфактантов, содержащая аналоги сурфактантного белка в (sp-b) и сурфактантного белка с (sp-c)
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
PE20090682A1 (es) Secuencias peptidicas y composiciones
EA202192555A1 (ru) Комбинированная терапия для лечения рака
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
CL2021000938A1 (es) Composiciones estables de semaglutida y usos de las mismas
CU20220066A7 (es) Péptidos inmunogénicos útiles en el tratamiento de esclerosis múltiple
AR092279A1 (es) Pirrol carboxamidas fluorometilo sustituidas
BR112022008087A2 (pt) Composições tensoativas concentradas substancialmente anidras
PE20190375A1 (es) Inhibidor de esterasa c1 conjugado y sus usos
EA202192793A1 (ru) Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью
CL2023002583A1 (es) Ligandos peptídicos del receptor 3 de somatostatina restringidos conformacionales y sus conjugados y sus usos.
ATE342914T1 (de) Peptidanaloge als selektive inhibitoren der thrombinaktivierung des durch protease aktivierten rezeptors
EA202092190A1 (ru) Композиции и способы для лечения сильного запора
GB201917723D0 (en) Stable liquid formulations of glucagon-like peptide 1 or analogues thereof